Journal: Stem Cell Research & Therapy

Article Title: Extracellular vesicles derived from umbilical cord mesenchymal stromal cells alleviate pulmonary fibrosis by means of transforming growth factor-β signaling inhibition

doi: 10.1186/s13287-021-02296-8

Figure Lengend Snippet: uMSC-EVs inhibited TGF-β2 and TGF-βR2 expression in lung tissues of BLM-induced mice. a , b Expression levels of TGF-β2 and TGF-βR2 were detected using IF staining and qRT-PCR. Scale bar = 200 μm. Mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.001; n = 5. TGF-β2, transforming growth factor-β2; TGF-βR2, transforming growth factor-β receptor type II

Article Snippet: The primary antibodies used in the study were anti-Ki67 (bs-23105R, Bioss, China), anti-α-SMA (bsm-33188M, Bioss, China), anti-fibronectin (anti-Fn; bs-0666R, Bioss, China), anti-transforming growth factor-β1 (anti-TGF-β1; bsm33345M, Bioss, China), anti-transforming growth factor-β2 (anti-TGF-β2; bs-20412R, Bioss, China), anti-transforming growth factor-β3 (anti-TGF-β3; AF8142, Beyotime, China), anti-transforming growth factor-β receptor type I (anti-TGF-βR1; bs0638R, Bioss, China), and anti-transforming growth factor-β receptor type II (anti-TGF-βR2; AF8151, Beyotime, China).

Techniques: Expressing, Staining, Quantitative RT-PCR

Journal: Stem Cell Research & Therapy

Article Title: Extracellular vesicles derived from umbilical cord mesenchymal stromal cells alleviate pulmonary fibrosis by means of transforming growth factor-β signaling inhibition

doi: 10.1186/s13287-021-02296-8

Figure Lengend Snippet: uMSC-EVs inhibited TGF-β2 and TGF-βR2 expression in lung tissues of BLM-induced mice. a , b Expression levels of TGF-β2 and TGF-βR2 were detected using IF staining and qRT-PCR. Scale bar = 200 μm. Mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.001; n = 5. TGF-β2, transforming growth factor-β2; TGF-βR2, transforming growth factor-β receptor type II

Article Snippet: The primary antibodies used in the study were anti-Ki67 (bs-23105R, Bioss, China), anti-α-SMA (bsm-33188M, Bioss, China), anti-fibronectin (anti-Fn; bs-0666R, Bioss, China), anti-transforming growth factor-β1 (anti-TGF-β1; bsm33345M, Bioss, China), anti-transforming growth factor-β2 (anti-TGF-β2; bs-20412R, Bioss, China), anti-transforming growth factor-β3 (anti-TGF-β3; AF8142, Beyotime, China), anti-transforming growth factor-β receptor type I (anti-TGF-βR1; bs0638R, Bioss, China), and anti-transforming growth factor-β receptor type II (anti-TGF-βR2; AF8151, Beyotime, China).

Techniques: Expressing, Staining, Quantitative RT-PCR

Journal: Stem Cell Research & Therapy

Article Title: Extracellular vesicles derived from umbilical cord mesenchymal stromal cells alleviate pulmonary fibrosis by means of transforming growth factor-β signaling inhibition

doi: 10.1186/s13287-021-02296-8

Figure Lengend Snippet: uMSC-EVs inhibited TGF-β1-induced myofibroblast differentiation in vitro. WML2 fibroblast cells were cultured for 48 h with TGF-β1 to induce myofibroblast differentiation, some of the cells were also treated with uMSC-EVs as indicated, then expression levels of α-SMA ( a , b ), TGF-β2 ( c , d ), and TGF-βR2 ( c , e ) were detected in different treatments using qRT-PCR and IF. Scale bar = 200 μm. Mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.001; n = 3. TGF-β1, transforming growth factor-β1

Article Snippet: The primary antibodies used in the study were anti-Ki67 (bs-23105R, Bioss, China), anti-α-SMA (bsm-33188M, Bioss, China), anti-fibronectin (anti-Fn; bs-0666R, Bioss, China), anti-transforming growth factor-β1 (anti-TGF-β1; bsm33345M, Bioss, China), anti-transforming growth factor-β2 (anti-TGF-β2; bs-20412R, Bioss, China), anti-transforming growth factor-β3 (anti-TGF-β3; AF8142, Beyotime, China), anti-transforming growth factor-β receptor type I (anti-TGF-βR1; bs0638R, Bioss, China), and anti-transforming growth factor-β receptor type II (anti-TGF-βR2; AF8151, Beyotime, China).

Techniques: In Vitro, Cell Culture, Expressing, Quantitative RT-PCR

Journal: Stem Cell Research & Therapy

Article Title: Extracellular vesicles derived from umbilical cord mesenchymal stromal cells alleviate pulmonary fibrosis by means of transforming growth factor-β signaling inhibition

doi: 10.1186/s13287-021-02296-8

Figure Lengend Snippet: uMSC-EV-specific miRNAs target TGF-β2 and TGF-βR2 to inhibit myofibroblast differentiation. a Main miRNAs in uMSC-EVs using qRT-PCR. b A list of predicted binding sites of uMSC-EV-specific miRNAs and their targets. c – e Effect of uMSC-EV-specific miRNAs (mimics) on the expression levels of α-SMA, TGF-β2, and TGF-βR2 in TGF-β1-induced WML2 fibroblast cells (5 ng/mL) using IF and qRT-PCR. Scale bar = 200 μm. Mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.001; n = 3

Article Snippet: The primary antibodies used in the study were anti-Ki67 (bs-23105R, Bioss, China), anti-α-SMA (bsm-33188M, Bioss, China), anti-fibronectin (anti-Fn; bs-0666R, Bioss, China), anti-transforming growth factor-β1 (anti-TGF-β1; bsm33345M, Bioss, China), anti-transforming growth factor-β2 (anti-TGF-β2; bs-20412R, Bioss, China), anti-transforming growth factor-β3 (anti-TGF-β3; AF8142, Beyotime, China), anti-transforming growth factor-β receptor type I (anti-TGF-βR1; bs0638R, Bioss, China), and anti-transforming growth factor-β receptor type II (anti-TGF-βR2; AF8151, Beyotime, China).

Techniques: Quantitative RT-PCR, Binding Assay, Expressing